Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safet ...
Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safet ...